{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:26:45Z","timestamp":1750444005605,"version":"3.38.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,27]]},"DOI":"10.7759\/cureus.79772","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T18:35:36Z","timestamp":1740681336000},"source":"Crossref","is-referenced-by-count":1,"title":["Venous Thromboembolism Prophylaxis Compliance in Orthopedic Patients With Cardiac Risk Factors"],"prefix":"10.7759","author":[{"given":"Usama","family":"Asif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usman","family":"Ghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheikh Muhammad Rehman","family":"Zia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhan","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Usman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aqsa","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humna","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal","family":"Qammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci11030049","article-title":"Venous thromboembolism prophylaxis in major orthopedic surgeries and factor XIa inhibitors","volume":"11","author":"Jones A","year":"2023","unstructured":"Jones A, Al-Horani RA. Venous thromboembolism prophylaxis in major orthopedic surgeries and factor XIa inhibitors. Med Sci (Basel). 2023, 11:49. 10.3390\/medsci11030049","journal-title":"Med Sci (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005134.pub3","article-title":"Pentasaccharides for the prevention of venous thromboembolism","volume":"10","author":"Dong K","year":"2016","unstructured":"Dong K, Song Y, Li X, Ding J, Gao Z, Lu D, Zhu Y. Pentasaccharides for the prevention of venous thromboembolism. Cochrane Database Syst Rev. 2016, 10:CD005134. 10.1002\/14651858.CD005134.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2005.05.023","article-title":"Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery","volume":"21","author":"Colwell CW Jr","year":"2006","unstructured":"Colwell CW Jr, Kwong LM, Turpie AG, Davidson BL. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty. 2006, 21:36-45. 10.1016\/j.arth.2005.05.023","journal-title":"J Arthroplasty"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1269","article-title":"The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery","volume":"33","author":"Mahmoudi M","year":"2013","unstructured":"Mahmoudi M, Sobieraj DM. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery. Pharmacotherapy. 2013, 33:1333-40. 10.1002\/phar.1269","journal-title":"Pharmacotherapy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02360-9","article-title":"Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients","volume":"52","author":"Gibson CM","year":"2021","unstructured":"Gibson CM, Hall C, Davis S, Schillig JM. Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients. J Thromb Thrombolysis. 2021, 52:577-83. 10.1007\/s11239-020-02360-9","journal-title":"J Thromb Thrombolysis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/0268355520947300","article-title":"Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: a real word cohort study - the SeVEN EXTension study","volume":"36","author":"Karathanos C","year":"2021","unstructured":"Karathanos C, Chatzis D, Latzios P, Papakostas I, Goumas K, Giannoukas AD. Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: a real word cohort study - the SeVEN EXTension study. Phlebology. 2021, 36:423-31. 10.1177\/0268355520947300","journal-title":"Phlebology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13566","article-title":"Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis","volume":"15","author":"Kapoor A","year":"2017","unstructured":"Kapoor A, Ellis A, Shaffer N, et al.. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J Thromb Haemost. 2017, 15:284-94. 10.1111\/jth.13566","journal-title":"J Thromb Haemost"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13416","article-title":"Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial","volume":"328","author":"Sidhu VS","year":"2022","unstructured":"Sidhu VS, Kelly TL, Pratt N, et al.. Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial. JAMA. 2022, 328:719-27. 10.1001\/jama.2022.13416","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2021.55","article-title":"Role of direct oral anticoagulants for post-operative venous thromboembolism prophylaxis","volume":"17","author":"Tun HN","year":"2022","unstructured":"Tun HN, Kyaw MT, Rafflenbeul E, Su\u00e1stegui XL. Role of direct oral anticoagulants for post-operative venous thromboembolism prophylaxis. Eur Cardiol. 2022, 17:e11. 10.15420\/ecr.2021.55","journal-title":"Eur Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.09.011","article-title":"Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial","volume":"134","author":"Fuji T","year":"2014","unstructured":"Fuji T, Wang CJ, Fujita S, et al.. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res. 2014, 134:1198-204. 10.1016\/j.thromres.2014.09.011","journal-title":"Thromb Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-07-0527","article-title":"Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty","volume":"115","author":"Kim SM","year":"2016","unstructured":"Kim SM, Moon YW, Lim SJ, Kim DW, Park YS. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. Thromb Haemost. 2016, 115:600-7. 10.1160\/TH15-07-0527","journal-title":"Thromb Haemost"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59497","article-title":"Racial and socioeconomic determinants of cardiovascular health: a comprehensive review","volume":"16","author":"Borkowski P","year":"2024","unstructured":"Borkowski P, Borkowska N, Mangeshkar S, Adal BH, Singh N. Racial and socioeconomic determinants of cardiovascular health: a comprehensive review. Cureus. 2024, 16:e59497. 10.7759\/cureus.59497","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin KA","year":"2021","unstructured":"Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021, 19:1874-82. 10.1111\/jth.15358","journal-title":"J Thromb Haemost"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-016-0121-1","article-title":"Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials","volume":"14","author":"Kawai Y","year":"2016","unstructured":"Kawai Y, Fuji T, Fujita S, Kimura T, Ibusuki K, Abe K, Tachibana S. Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials. Thromb J. 2016, 14:48. 10.1186\/s12959-016-0121-1","journal-title":"Thromb J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002247","article-title":"Effects of a foot pump on the incidence of deep vein thrombosis after total knee arthroplasty in patients given edoxaban: a randomized controlled study","volume":"95","author":"Sakai T","year":"2016","unstructured":"Sakai T, Izumi M, Kumagai K, et al.. Effects of a foot pump on the incidence of deep vein thrombosis after total knee arthroplasty in patients given edoxaban: a randomized controlled study. Medicine (Baltimore). 2016, 95:e2247. 10.1097\/MD.0000000000002247","journal-title":"Medicine (Baltimore)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4055\/cios.2017.9.1.37","article-title":"Intermittent pneumatic compression for the prevention of venous thromboembolism after total hip arthroplasty","volume":"9","author":"Kwak HS","year":"2017","unstructured":"Kwak HS, Cho JH, Kim JT, Yoo JJ, Kim HJ. Intermittent pneumatic compression for the prevention of venous thromboembolism after total hip arthroplasty. Clin Orthop Surg. 2017, 9:37-42. 10.4055\/cios.2017.9.1.37","journal-title":"Clin Orthop Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2020.1705783","article-title":"Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present)","volume":"30","author":"Al-Horani RA","year":"2020","unstructured":"Al-Horani RA. Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present). Expert Opin Ther Pat. 2020, 30:39-55. 10.1080\/13543776.2020.1705783","journal-title":"Expert Opin Ther Pat"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco A","year":"2023","unstructured":"Greco A, Laudani C, Spagnolo M, et al.. Pharmacology and clinical development of factor XI inhibitors. Circulation. 2023, 147:897-913. 10.1161\/CIRCULATIONAHA.122.062353","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/340636-venous-thromboembolism-prophylaxis-compliance-in-orthopedic-patients-with-cardiac-risk-factors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T18:35:37Z","timestamp":1740681337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/340636-venous-thromboembolism-prophylaxis-compliance-in-orthopedic-patients-with-cardiac-risk-factors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.79772","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}